Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: fenretinide Clear all
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

NCT00104923
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
fenretinide
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Children With Solid Tumors

NCT00003191
View directory record Official record
Conditions
Neuroblastoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
fenretinide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
25
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

NCT00646230
View directory record Official record
Conditions
Neuroblastoma
Interventions
fenretinide, high performance liquid chromatography, pharmacological study
Drug · Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
0 Years to 30 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 1Phase 2 Interventional

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

NCT01535157
View directory record Official record
Conditions
Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma
Interventions
Fenretinide/LXS + Ketoconazole
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

NCT00001378
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
fenretinide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

NCT04234048
View directory record Official record
Conditions
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma

NCT00295919
View directory record Official record
Conditions
Neuroblastoma
Interventions
fenretinide lipid matrix, ketoconazole, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
0 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome

NCT00003601
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
fenretinide, tretinoin
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 2 Interventional

SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

NCT00003223
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fenretinide
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
15
States / cities
Tucson, Arizona • Kansas City, Kansas • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Examine the Effects of Oral Fenretinide

NCT06528457
View directory record Official record
Conditions
Dengue
Interventions
ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo
Drug · Other
Lead sponsor
Island Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma

NCT00589381
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide lipid matrix
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional Results available

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

NCT03265288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Fenretinide in Treating Patients With Solid Tumors

NCT00003250
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fenretinide
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00006471
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Fenretinide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Sep 2, 2026, 5:47 PM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Solid Tumors

NCT00009932
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, fenretinide, paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

NCT00003099
View directory record Official record
Conditions
Breast Cancer
Interventions
Fenretinide, Tamoxifen Citrate, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2012 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Not applicable Interventional

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

NCT00098800
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
fenretinide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent Malignant Glioma

NCT00006080
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
fenretinide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL

NCT01187810
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
Interventions
Fenretinide, Cytarabine, Methotrexate
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
Up to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 2, 2026, 5:47 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

NCT06922539
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

NCT01553071
View directory record Official record
Conditions
Solid Tumor
Interventions
Fenretinide (4-HPR) plus Intravenous Safingol
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Dallas, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 2, 2026, 5:47 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

NCT00005819
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cisplatin, fenretinide, paclitaxel
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 2, 2026, 5:47 PM EDT
Terminated Phase 1 Interventional

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT00102635
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Fenretinide (4-HPR), SCH66336
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Sep 2, 2026, 5:47 PM EDT
Suspended Phase 2 Interventional Results available

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

NCT00546455
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Fenretinide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2099
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 2, 2026, 5:47 PM EDT